Please assess the completion status of the following clinical trial:

Trial Title: Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)~* Received 1 or 2 prior treatment regimens for advanced or metastatic disease~* Confirmed radiologic disease progression during or following recent treatment~* Mandatory biopsy is required during screening~* Measurable disease per RECIST v1.1~* Adequate organ function~* ECOG 0 or 1~Exclusion Criteria:~* Prior treatment with a PARP inhibitor~* Symptomatic and/or untreated CNS metastases~* Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rucaparib (Type: EXPERIMENTAL): Oral rucaparib (monotherapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).